Highly active antiretroviral treatment against STLV-1 infection combining reverse transcriptase and HDAC inhibitors

Blood

Volumn 116, Issue 19, 2010, Pages 3802-3808

  Afonso, Philippe V ^a   Mekaouche, Mourad ^a   Mortreux, Franck ^b   Toulza, Frédéric ^c   Moriceau, Antoine ^d   Wattel, Eric ^b   Gessain, Antoine ^a   Bangham, Charles R M ^c   Dubreuil, Guy ^a   Plumelle, Yves ^e   Hermine, Olivier ^a   Estaquier, Jérome ^f   Mahieux, Renaud ^a,g  

^a CNRS   (France)

^b CENTRE LÉON BÉRARD   (France)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e CENTRE HOSPITALIER UNIVERSITAIRE DE FORT DE FRANCE   (France)

^f HENRI MONDOR HOSPITAL   (France)

^g University Lyon i   (France)

Author keywords

[No Author keywords available]

Indexed keywords

VALPROIC ACID; ZIDOVUDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BABOON; CD8+ T LYMPHOCYTE; CELL POPULATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG POTENTIATION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN T CELL LEUKEMIA VIRUS; MALE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; RETROVIRUS INFECTION; VIRUS LOAD;

EID: 78149442762     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-02-270751     Document Type: Article

References (43)

1. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A. 1980;77(12):7415-7419.
2. Yoshida M, Miyoshi I, Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci U S A. 1982;79(6):2031-2035. (Pubitemid 12088563)
3. Gessain A, Barin F, Vernant JC, et al. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet. 1985;2(8452):407-410. (Pubitemid 15231248)
4. Osame M, Usuku K, Izumo S, et al. HTLV-I associated myelopathy, a new clinical entity. Lancet. 1986;1(8488):1031-1032. (Pubitemid 16102987)
5. Rodgers-Johnson P, Gajdusek DC, Morgan OS, Zaninovic V, Sarin PS, Graham DS. HTLV-I and HTLV-III antibodies and tropical spastic paraparesis. Lancet. 1985;2(8466):1247-1248. (Pubitemid 16203874)
6. Bittencourt AL, Primo J, Oliveira MF. Manifestations of the human T-cell lymphotropic virus type I infection in childhood and adolescence. J Pediatr (Rio J). 2006;82(6):411-420. (Pubitemid 44917410)
7. Kira J, Fujihara K, Itoyama Y, Goto I, Hasuo K. Leukoencephalopathy in HTLV-I-associated myelopathy/tropical spastic paraparesis: MRI analysis and a two year follow-up study after corticosteroid therapy. J Neurol Sci. 1991;106(1):41-49.
8. Lehky TJ, Levin MC, Kubota R, et al. Reduction in HTLV-I proviral load and spontaneous lymphoproliferation in HTLV-I-associated myelopathy/tropical spastic paraparesis patients treated with humanized anti-Tac. Ann Neurol. 1998;44(6):942-947. (Pubitemid 28558256)
9. Lezin A, Gillet N, Olindo S, et al. Histone deacetylase mediated transcriptional activation reduces proviral loads in HTLV-1 associated myelopathy/tropical spastic paraparesis patients. Blood. 2007;110(10):3722-3728. (Pubitemid 350159642)
10. Taylor GP, Goon P, Furukawa Y, et al. Zidovudine plus lamivudine in Human T-Lymphotropic Virus type-I-associated myelopathy: a randomised trial. Retrovirology. 2006;3:63. (Pubitemid 44541907)
11. Bhigjee AI, Wiley CA, Wachsman W, et al. HTLVI- associated myelopathy: clinicopathologic correlation with localization of provirus to spinal cord. Neurology. 1991;41(12):1990-1992.
12. Nagai M, Brennan MB, Sakai JA, Mora CA, Jacobson S. CD8(+) T cells are an in vivo reservoir for human T-cell lymphotropic virus type I. Blood. 2001;98(6):1858-1861.
13. Hanon E, Stinchcombe JC, Saito M, et al. Fratricide among CD8(+) T lymphocytes naturally infected with human T cell lymphotropic virus type I. Immunity. 2000;13(5):657-664.
14. Afonso PV, Ozden S, Cumont MC, et al. Alteration of blood-brain barrier integrity by retroviral infection. PLoS Pathog. 2008;4(11):e1000205.
15. Ceccaldi PE, Delebecque F, Prevost MC, et al. DC-SIGN facilitates fusion of dendritic cells with human T-cell leukemia virus type 1-infected cells. J Virol. 2006;80(10):4771-4780.
16. Jones KS, Petrow-Sadowski C, Huang YK, Bertolette DC, Ruscetti FW. Cell-free HTLV-1 infects dendritic cells leading to transmission and transformation of CD4(+) T cells. Nat Med. 2008;14(4):429-436. (Pubitemid 351499395)
17. Olindo S, Lezin A, Cabre P, et al. HTLV-1 proviral load in peripheral blood mononuclear cells quantified in 100 HAM/TSP patients: a marker of disease progression. J Neurol Sci. 2005;237(1):53-59. (Pubitemid 41384014)
18. Olindo S, Cabre P, Lezin A, et al. Natural history of human T-lymphotropic virus 1-associated myelopathy: a 14-year follow-up study. Arch Neurol. 2006;63(11):1560-1566. (Pubitemid 44748798)
19. Nagai M, Usuku K, Matsumoto W, et al. Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP. J Neurovirol. 1998;4(6):586-593. (Pubitemid 29042065)
20. Takenouchi N, Yamano Y, Usuku K, Osame M, Izumo S. Usefulness of proviral load measurement for monitoring of disease activity in individual patients with human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis. J Neurovirol. 2003;9(1):29-35. (Pubitemid 36372543)
21. Matsuzaki T, Nakagawa M, Nagai M, et al. HTLV-I proviral load correlates with progression of motor disability in HAM/TSP: analysis of 239 HAM/TSP patients including 64 patients followed up for 10 years. J Neurovirol. 2001;7(3):228-234. (Pubitemid 32685257)
22. Jeffery KJ, Siddiqui AA, Bunce M, et al. The influence of HLA class I alleles and heterozygosity on the outcome of human T cell lymphotropic virus type I infection. J Immunol. 2000;165(12):7278-7284.
23. Jeffery KJ, Usuku K, Hall SE, et al. HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy. Proc Natl Acad Sci U S A. 1999;96(7):3848-3853.
24. Bangham CR. The immune control and cell-tocell spread of human T-lymphotropic virus type 1. J Gen Virol. 2003;84(12):3177-3189.
25. Saito M, Nakagawa M, Kaseda S, et al. Decreased human T lymphotropic virus type I (HTLV-I) provirus load and alteration in T cell phenotype after interferon-alpha therapy for HTLV-I-associated myelopathy/tropical spastic paraparesis. J Infect Dis. 2004;189(1):29-40.
26. Mortreux F, Gabet AS, Wattel E. Molecular and cellular aspects of HTLV-1 associated leukemogenesis in vivo. Leukemia. 2003;17(1):26-38.
27. Taniguchi Y, Nosaka K, Yasunaga J, et al. Silencing of human T-cell leukemia virus type I gene transcription by epigenetic mechanisms. Retrovirology. 2005;2:64.
28. Ego T, Ariumi Y, Shimotohno K. The interaction of HTLV-1 Tax with HDAC1 negatively regulates the viral gene expression. Oncogene. 2002;21(47):7241-7246.
29. Lu H, Pise-Masison CA, Linton R, et al. Tax relieves transcriptional repression by promoting histone deacetylase 1 release from the human T-cell leukemia virus type 1 long terminal repeat. J Virol. 2004;78(13):6735-6743.
30. Lagneaux L, Gillet N, Stamatopoulos B, et al. Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response. Exp Hematol. 2007;35(10):1527-1537.
31. Nishioka C, Ikezoe T, Yang J, et al. Histone deacetylase inhibitors induce growth arrest and apoptosis of HTLV-1-infected T cells via blockade of signaling by nuclear factor kappaB. Leuk Res. 2008;32(2):287-296.
32. Lezin A, Olindo S, Belrose G, et al. Gene activation therapy: from the BLV model to HAM/TSP patients. Front Biosci (Schol Ed). 2009;1:205-215.
33. Toulza F, Nosaka K, Takiguchi M, et al. FoxP3(+) regulatory T cells are distinct from leukemia cells in HTLV-1-associated adult T-cell leukemia. Int J Cancer. 2009;125(10):2375-2382.
34. Wolfe ND, Heneine W, Carr JK, et al. Emergence of unique primate T-lymphotropic viruses among central African bushmeat hunters. Proc Natl Acad Sci U S A. 2005;102(22):7994-7999. (Pubitemid 40781051)
35. Allan JS, Leland M, Broussard S, Mone J, Hubbard G. Simian T-cell lymphotropic Viruses (STLVs) and lymphomas in African nonhuman primates. Cancer Invest. 2001;19(4):383-395. (Pubitemid 32525186)
36. Gabet AS, Mortreux F, Talarmin A, et al. High circulating proviral load with oligoclonal expansion of HTLV-1 bearing T cells in HTLV-1 carriers with strongyloidiasis. Oncogene. 2000;19(43):4954-4960.
37. Monceaux V, Ho Tsong Fang R, Cumont MC, Hurtrel B, Estaquier J. Distinct cycling CD4(+)- and CD8(+)-T-cell profiles during the asymptomatic phase of simian immunodeficiency virus SIV-mac251 infection in rhesus macaques. J Virol. 2003;77(18):10047-10059. (Pubitemid 37122086)
38. Asquith B, Mosley AJ, Heaps A, et al. Quantification of the virus-host interaction in human T lymphotropic virus I infection. Retrovirology. 2005;2:75. (Pubitemid 41829869)
39. Lee B, Tanaka Y, Tozawa H. Monoclonal antibody defining tax protein of human T-cell leukemia virus type-I. Tohoku J Exp Med. 1989;157(1):1-11. (Pubitemid 19086129)
40. Nagai M, Kubota R, Greten TF, Schneck JP, Leist TP, Jacobson S. Increased activated human T cell lymphotropic virus type I (HTLV-I) Tax11-19-specific memory and effector CD8+ cells in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis: correlation with HTLV-I provirus load. J Infect Dis. 2001;183(2):197-205. (Pubitemid 32066019)
41. Gout O, Gessain A, Iba-Zizen M, et al. The effect of zidovudine on chronic myelopathy associated with HTLV-1. J Neurol. 1991;238(2):108-109.
42. Sheremata WA, Benedict D, Squilacote DC, Sazant A, DeFreitas E. High-dose zidovudine induction in HTLV-I-associated myelopathy: safety and possible efficacy. Neurology. 1993;43(10):2125-2129. (Pubitemid 23318891)
43. Iwanaga M, Watanabe T, Utsunomiya A, et al. Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. Blood. 2010;116(8):1211-1219.